Report of the use of patient‐derived xenograft models in the development of anticancer drugs in Japan. Issue 9 (28th July 2020)

• Record Type: Journal Article
• Authors: Tsumura, Ryo; Koga, Yoshikatsu; Hamada, Akinobu; Kuwata, Takeshi; Sasaki, Hiroki; Doi, Toshihiko; Aikawa, Katsuji; Ohashi, Akihiro; Katano, Ikumi; Ikarashi, Yoshinori; Ito, Mamoru; Ochiai, Atsushi
• Is Part Of: Cancer science. Volume 111:Issue 9(2020)
• Page Start: 3386
• Page End: 3394
• Publication Date: 2020-07-28
• Subjects: animal model -- drug development -- patient‐derived xenograft model -- questionnaire -- regulatory science; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.14564
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract: Cell line‐derived xenograft (CDX) models created by implanting cancer cell lines into immunodeficient mice have contributed largely to the development of cancer drug therapies. However, cell lines often lose their original biological characteristics through many passages and cancer tissues in CDX models have many cancer cells and few cancer stromal cells, therefore CDX models are currently considered not suitable for predicting the results of clinical studies. Conversely, patient‐derived xenograft (PDX) models are gaining importance, as human cancer biological characteristics and microenvironments are recreated by implanting tumor tissue into immunodeficient mice. These highly expected, evidently beneficial PDX models have been used in some basic research and are becoming more generalized. However, quality control and quality assurance criteria have not been established for them, and challenges and problems in the utilization of valuable PDX models in drug development have yet to be clarified. In this report, we conducted a questionnaire survey among researchers in Japanese academic institutions and pharmaceutical companies to understand the current status of PDX models in Japan. Based on the questionnaire results, we summarized the situations surrounding respondent's utilization and quality control in the development of anticancer drugs and proposed several measures to facilitate the utilization of PDX models in the development of anticancer drugs. Abstract : We conducted a questionnaire survey among researchers in Japanese academic institutions and pharmaceutical companies to understand the current status of PDX models in Japan. Based on the results of the survey, we proposed several measures to facilitate the utilization of PDX models in the development of anticancer drugs. It is hoped that this report provides information to undertake research using PDX models for the development of anticancer drugs.